Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIV4 Immunogenicity in Children, Adolescents, and Adults
NCT05513053Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of Quadrivalent recombinant influenza vaccine in influenza, sponsored by Sanofi. Started Oct 2022; status: completed.
02
Drugs
Quadrivalent recombinant influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05513053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513053.